for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DelMar Pharmaceuticals Inc

DMPI.OQ

Latest Trade

0.94USD

Change

0.00(-0.00%)

Volume

49,562

Today's Range

0.86

 - 

0.96

52 Week Range

0.38

 - 

2.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.94
Open
0.92
Volume
49,562
3M AVG Volume
19.85
Today's High
0.96
Today's Low
0.86
52 Week High
2.45
52 Week Low
0.38
Shares Out (MIL)
11.46
Market Cap (MIL)
10.93
Forward P/E
-1.47
Dividend (Yield %)
--

Next Event

DelMar Pharmaceuticals Inc Extraordinary Shareholders Meeting

Latest Developments

More

DelMar To Acquire Adgero Biopharmaceuticals

Delmar Pharmaceuticals Reports Q3 Loss Per Share $0.17

DelMar Pharmaceuticals Provides Enrollment Update In Phase 2 Clinical Trial Of Val-083 For Adjuvant Treatment Of Brain Tumors

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DelMar Pharmaceuticals Inc

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a first-in-class, small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).

Industry

Biotechnology & Drugs

Contact Info

12707 High Bluff Drive, Suite 200

SAN DIEGO, CA

92130

United States

+1.604.2021384

http://www.delmarpharma.com/

Executive Leadership

Robert E. Hoffman

Independent Chairman of the Board

Saiid Zarrabian

President, Chief Executive Officer, Director

Scott Praill

Chief Financial Officer

Dennis M. Brown

Chief Scientific Officer, Director

John K. Bell

Lead Independent Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-7.400

2018

-5.400

2019

-3.160

2020(E)

-0.650
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-316.70
Return on Equity (TTM)
-208.63

Latest News

Latest News

BRIEF-DelMar To Acquire Adgero Biopharmaceuticals

* DELMAR TO ACQUIRE ADGERO BIOPHARMACEUTICALS, EXPANDS LATE-STAGE ONCOLOGY PIPELINE

BRIEF-DelMar Pharmaceuticals' VAL-083 Selected To Participate In Global Coalition For Adaptive Research's GBM AGILE Pivotal Study

* GLOBAL COALITION FOR ADAPTIVE RESEARCH (GCAR) SELECTS DELMAR PHARMACEUTICALS' VAL-083 TO PARTICIPATE IN THE GBM AGILE PIVOTAL STUDY, AN ADAPTIVE CLINICAL TRIAL PLATFORM IN GLIOBLASTOMA MULTIFORME Source text for Eikon: Further company coverage:

BRIEF-Delmar Pharmaceuticals To Present Updates Of Two Phase 2 Clinical Trials Of Val-083 At 2020 American Association For Cancer Research Virtual Annual Meeting Ii

* DELMAR PHARMACEUTICALS TO PRESENT UPDATES OF TWO PHASE 2 CLINICAL TRIALS OF VAL-083 AT THE 2020 AMERICAN ASSOCIATION FOR CANCER RESEARCH VIRTUAL ANNUAL MEETING II Source text for Eikon: Further company coverage:

BRIEF-Delmar Pharmaceuticals Reports Q3 Loss Per Share $0.17

* DELMAR PHARMACEUTICALS ANNOUNCES FISCAL THIRD QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES

BRIEF-DelMar Pharmaceuticals Provides Enrollment Update In Phase 2 Clinical Trial Of Val-083 For Adjuvant Treatment Of Brain Tumors

* DELMAR PHARMACEUTICALS [NASDAQ:DMPI] PROVIDES ENROLLMENT UPDATE IN PHASE 2 CLINICAL TRIAL OF VAL-083 FOR ADJUVANT TREATMENT OF BRAIN TUMORS

BRIEF-DelMar Pharmaceuticals Reports Over 50% Enrollment In Phase 2 Clinical Trial Of VAL-083 For Adjuvant Treatment Of Brain Tumors

* DELMAR PHARMACEUTICALS [NASDAQ:DMPI] REPORTS OVER 50% ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF VAL-083 FOR ADJUVANT TREATMENT OF BRAIN TUMORS

BRIEF-Delmar Pharma Enrolls Final Patient In Phase 2 Clinical Trial Of Val-083 For First-Line Treatment Of Brain Tumors

* DELMAR PHARMACEUTICALS [NASDAQ:DMPI] ENROLLS FINAL PATIENT IN PHASE 2 CLINICAL TRIAL OF VAL-083 FOR FIRST-LINE TREATMENT OF BRAIN TUMORS

BRIEF-Delmar Appoints Saiid Zarrabian Full-Time President And CEO

* DELMAR APPOINTS SAIID ZARRABIAN TO FULL-TIME PRESIDENT AND CEO

BRIEF-DelMar Pharmaceuticals Reports Q3 Loss Per Share Of $0.13

* DELMAR PHARMACEUTICALS ANNOUNCES THIRD QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM

BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share From 50 Mln Shares To 70 Mln Shares

* TO INCREASE NUMBER OF AUTHORIZED SHARES OF STOCK, PAR VALUE OF $0.001, PER SHARE FROM 50 MILLION SHARES TO 70 MILLION SHARES Source text: (https://bit.ly/2GWHkzx) Further company coverage:

BRIEF-Delmar Pharmaceuticals Q2 Loss Per Share $0.14

* DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

BRIEF-DelMar Pharmaceuticals Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma

* DELMAR PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR VAL-083 IN RECURRENT GLIOBLASTOMA

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage:

BRIEF-Delmar Pharmaceuticals names Saiid Zarrabian interim CEO

* Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer

BRIEF-DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6

* DelMar Pharmaceuticals Inc CEO Jeffrey Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing Source text: (http://bit.ly/2kDnPBr) Further company coverage:

BRIEF-DelMar Pharmaceuticals announces $10 million registered direct offering

* Announces $10 million registered direct offering priced at-the-market

BRIEF-Delmar Pharmaceuticals receives IND allowance from FDA

* Delmar Pharmaceuticals receives IND allowance from FDA to initiate clinical trials of VAL-083 for the treatment of ovarian cancer Source text for Eikon: Further company coverage:

BRIEF-Delmar Pharmaceuticals initiates phase 2 clinical trial

* Delmar Pharmaceuticals initiates phase 2 clinical trial in newly diagnosed MGMT-unmethylated glioblastoma multiforme

BRIEF-Delmar Pharmaceuticals HGRAC approves application to initiate phase 2 of VAL-083

* Delmar Pharmaceuticals receives approval from China's Human Genetic Resources Administration to initiate phase 2 clinical trial in newly diagnosed GBM

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up